FDA grants priority review for Roche’s Enspryng for Mogad
Roche Holding AG received a U.S. FDA priority review for its Enspryng for Mogad.
Story updates
05:04:43 AM UTC
SquawkNews
Phase III MeteorOid Study Showed 68% Reduction In Relapse Risk - FDA Decision Expected By 10 January 2027 - EMA Validates European Application For Enspryng In MOGAD - European Commission Decision Expected In Q3 2027
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.